To include your compound in the COVID-19 Resource Center, submit it here.

Kancera's KAND567 well tolerated in Phase I

Kancera AB (SSE:KAN) reported data from a Phase I trial in 82 healthy volunteers

Read the full 149 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE